Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study
<p dir="ltr">Consortia like the Clinical Pharmacogenetic Implementation Consortium (CPIC) and the Dutch Pharmacogenetic Working Group (DPWG) provide clinical guidelines but pharmacogenomics implementation depends on population prevalence of actionable genetic variants and response ph...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513534583373824 |
|---|---|
| author | Dinesh Velayutham (5444072) |
| author2 | Kholoud Bastaki (18434094) Areeba Irfan (19255795) Mohammed Abuhaliqa (18434091) Aisha AlMulla (22466677) the Qatar Genome Program Research Consortium (22466680) Suhaila Ghuloum (796180) Muhammad Waqar Azeem (11909633) Munir Pirmohamed (40546) Puthen Veettil Jithesh (12040358) |
| author2_role | author author author author author author author author author |
| author_facet | Dinesh Velayutham (5444072) Kholoud Bastaki (18434094) Areeba Irfan (19255795) Mohammed Abuhaliqa (18434091) Aisha AlMulla (22466677) the Qatar Genome Program Research Consortium (22466680) Suhaila Ghuloum (796180) Muhammad Waqar Azeem (11909633) Munir Pirmohamed (40546) Puthen Veettil Jithesh (12040358) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dinesh Velayutham (5444072) Kholoud Bastaki (18434094) Areeba Irfan (19255795) Mohammed Abuhaliqa (18434091) Aisha AlMulla (22466677) the Qatar Genome Program Research Consortium (22466680) Suhaila Ghuloum (796180) Muhammad Waqar Azeem (11909633) Munir Pirmohamed (40546) Puthen Veettil Jithesh (12040358) |
| dc.date.none.fl_str_mv | 2025-04-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1017/pcm.2025.2 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Clinically_actionable_pharmacogenomic_landscape_of_antidepressants_and_antipsychotics_in_Qatar_a_population-based_cohort_study/30405586 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Genetics Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Precision medicine Pharmacogenomics Psychotropics Whole genome sequencing Clinical implementation |
| dc.title.none.fl_str_mv | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Consortia like the Clinical Pharmacogenetic Implementation Consortium (CPIC) and the Dutch Pharmacogenetic Working Group (DPWG) provide clinical guidelines but pharmacogenomics implementation depends on population prevalence of actionable genetic variants and response phenotypes. We analyzed the distribution of actionable genetic variants and clinical recommendations in 14,354 adult Qataris, focusing only genes with guidelines (<i>CYP2C19, CYP2D6, CYP2B6 </i>and<i> CYP3A4</i>). Haplotypes and diplotypes were generated from 490 alleles using whole genome data and metabolizer phenotypes were predicted based on current knowledge. Qatari population predicted to have actionable metabolizer phenotypes of CYP2C19, CYP2B6 and CYP2D6 impacting response to antidepressants were in the range of 1%–58% and for antipsychotics 0.1%–33% based on <i>CYP3A4 </i>and<i> CYP2D6</i>. Fine-grained analysis based on clinical guidelines also revealed that while the Qataris may need prescription of an alternate antidepressant not metabolized by CYP2C19, patients from other populations may just need altering the dosage of tricyclic antidepressants like amitriptyline. Further studies incorporating other factors such as diet, environment and cultural habits along with population-specific variants will help in the pharmacogenomics implementation in the Qatari population.</p><h2>Other Information</h2><p dir="ltr">Published in: Cambridge Prisms: Precision Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">http://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1017/pcm.2025.2" target="_blank">https://dx.doi.org/10.1017/pcm.2025.2</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_9731c336e5f1f6b1b5ff0083416c90d7 |
| identifier_str_mv | 10.1017/pcm.2025.2 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30405586 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort studyDinesh Velayutham (5444072)Kholoud Bastaki (18434094)Areeba Irfan (19255795)Mohammed Abuhaliqa (18434091)Aisha AlMulla (22466677)the Qatar Genome Program Research Consortium (22466680)Suhaila Ghuloum (796180)Muhammad Waqar Azeem (11909633)Munir Pirmohamed (40546)Puthen Veettil Jithesh (12040358)Biological sciencesGeneticsBiomedical and clinical sciencesPharmacology and pharmaceutical sciencesPrecision medicinePharmacogenomicsPsychotropicsWhole genome sequencingClinical implementation<p dir="ltr">Consortia like the Clinical Pharmacogenetic Implementation Consortium (CPIC) and the Dutch Pharmacogenetic Working Group (DPWG) provide clinical guidelines but pharmacogenomics implementation depends on population prevalence of actionable genetic variants and response phenotypes. We analyzed the distribution of actionable genetic variants and clinical recommendations in 14,354 adult Qataris, focusing only genes with guidelines (<i>CYP2C19, CYP2D6, CYP2B6 </i>and<i> CYP3A4</i>). Haplotypes and diplotypes were generated from 490 alleles using whole genome data and metabolizer phenotypes were predicted based on current knowledge. Qatari population predicted to have actionable metabolizer phenotypes of CYP2C19, CYP2B6 and CYP2D6 impacting response to antidepressants were in the range of 1%–58% and for antipsychotics 0.1%–33% based on <i>CYP3A4 </i>and<i> CYP2D6</i>. Fine-grained analysis based on clinical guidelines also revealed that while the Qataris may need prescription of an alternate antidepressant not metabolized by CYP2C19, patients from other populations may just need altering the dosage of tricyclic antidepressants like amitriptyline. Further studies incorporating other factors such as diet, environment and cultural habits along with population-specific variants will help in the pharmacogenomics implementation in the Qatari population.</p><h2>Other Information</h2><p dir="ltr">Published in: Cambridge Prisms: Precision Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">http://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1017/pcm.2025.2" target="_blank">https://dx.doi.org/10.1017/pcm.2025.2</a></p>2025-04-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1017/pcm.2025.2https://figshare.com/articles/journal_contribution/Clinically_actionable_pharmacogenomic_landscape_of_antidepressants_and_antipsychotics_in_Qatar_a_population-based_cohort_study/30405586CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304055862025-04-01T00:00:00Z |
| spellingShingle | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study Dinesh Velayutham (5444072) Biological sciences Genetics Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Precision medicine Pharmacogenomics Psychotropics Whole genome sequencing Clinical implementation |
| status_str | publishedVersion |
| title | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study |
| title_full | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study |
| title_fullStr | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study |
| title_full_unstemmed | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study |
| title_short | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study |
| title_sort | Clinically actionable pharmacogenomic landscape of antidepressants and antipsychotics in Qatar: a population-based cohort study |
| topic | Biological sciences Genetics Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Precision medicine Pharmacogenomics Psychotropics Whole genome sequencing Clinical implementation |